ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial [Video]

Amylyx Pharmaceuticals said Thursday it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.

The ALS drug, branded Albrioza in Canada and Relyvrio in the U.S., was approved in both countries in 2022.

ALS causes progressive paralysis and death. Each year about 1,000 Canadians die from the disease and about the same number are diagnosed, according to the ALS Society of Canada’s website. ALS affects roughly 60,000 people in the U.S. and Europe.

There are few options to treat the potentially fatal disease.

WATCH | ALS patient’s frustrations with delivery companies: Herman Jacobs says he often needs to make an “exhausting” 10-minute trip in his wheelchair to retrieve his parcels, when they are supposed to be dropped off at his door.

The medication is Amylyx’s only product on the market. The drug will no longer be available to new patients.

“Patients currently on …